| dc.contributor | 科管智財所 | |
| dc.creator (作者) | 陳秉訓 | |
| dc.creator (作者) | Chen, Ping-Hsun | |
| dc.date (日期) | 2021-06 | |
| dc.date.accessioned | 11-Apr-2022 14:32:38 (UTC+8) | - |
| dc.date.available | 11-Apr-2022 14:32:38 (UTC+8) | - |
| dc.date.issued (上傳時間) | 11-Apr-2022 14:32:38 (UTC+8) | - |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/139805 | - |
| dc.description.abstract (摘要) | This article reports Taiwan`s efforts to replicate remdesivir to prepare for combating COVID-19. There were two state-funded institutions and two private pharmaceutical companies working on remdesivir synthesis. They all claimed to successfully complete remdesivir of a high purity. But, since Gilead Sciences, Inc. has patented remdesivir in Taiwan, the Taiwan Government needs to initiate compulsory licensing under the Patent Act to start large-scale manufacturing of remdesivir within its territory. | |
| dc.format.extent | 230493 bytes | - |
| dc.format.mimetype | application/pdf | - |
| dc.relation (關聯) | Biotechnology Law Report, Vol.40, No.3, pp.174-183 | |
| dc.subject (關鍵詞) | Remdesivir;Taiwan;patent;COVID-19;compulsory licensing | |
| dc.title (題名) | Taiwan`s Efforts to Recreate Remdesivir | |
| dc.type (資料類型) | article | |
| dc.identifier.doi (DOI) | 10.1089/blr.2021.29227.phc | |
| dc.doi.uri (DOI) | http://doi.org/10.1089/blr.2021.29227.phc | |
